Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Antiviral Drugs. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN112759595B details a novel Pd-catalyzed asymmetric allylation for chiral nucleosides, offering high enantioselectivity and streamlined manufacturing for pharmaceutical intermediates.
Solve wastewater challenges in ribavirin intermediate manufacturing. New 3-step synthesis cuts waste by 70% with 84% yield. Ensure supply chain stability for API production.
Overcome low yield and complex purification in Favipiravir manufacturing. New one-pot method with 65% yield reduces costs and eliminates chromatography. Contact us for scalable production.
Solve pyrrole synthesis challenges with this mild, high-yield method. Reduce costs and supply chain risks for antibacterial/antiviral drug intermediates.
Solve low-yield and long-cycle issues in Paxlovid intermediate production. Our CDMO expertise delivers 60%+ yield, 99% purity, and industrial-scale reliability.
Discover how biocatalytic synthesis of chiral pseudonucleosides offers superior enantioselectivity, reduced waste, and cost-effective production for your antiviral and antitumor drug development.
Solve yield and safety issues in 6-chloro-2-methyl-2H-indazole-5-amine synthesis. Discover emerging green chemistry trends and find reliable suppliers for antiviral drug intermediates.